Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide vs Exenatide Brain Activity and Nausea Study
NCT02802514Phase 4Terminated
- Sponsor
- GSK
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Sep 2016; status: terminated.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02802514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802514.